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Group B was treated with carvedilol (same dosage) and CK at a dosage 
of 50 mg o.i.d. 
Cardiac volumes and ventricular function were assessed by echo at 
baseline and after 3 and 6 weeks. Quality of life was measured with MLHF 
questionnaire. 
Results: Left ventricular end-diastolic volume (LVEDV) was increased 
in B group less than in A group after three weeks (p -Z 0.05) and in B group 
was under baseline values after six weeks (p < 0.001). Left ventricular 
ejection fraction (EF) after three and six weeks in B group is alwais greater 
than A group (p < 0.001). 
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MLHF questionnaire was better in B group (p < 0.05). 
Conclusions: Canrenoate potassium, diuretic with positive neumhor- 
monal action, is useful in patients with heart failure treated with carvedilol, 
reducing the beta-blocker adverse effects during the first weeks. 
1 P59/10371 1 Biioprolol reduces episodes of ventricular tachycardia 
and sudden cardiac death in subjects with chronic 
heart failure 
B. Taneva, J. Davceva' , M. Vavlukis’, V. Andova’, N. Kostova’ Skopje; 
‘Cardiology Clinical Centec Skopje, FYROM 
Sixty-five subjects with mild to moderate chronic heart failure were 
randomized to recieve treatment: 32 or them ACE inhibitors, diuretics and 
digitalis and 33 of them the same tretment plus Bisoprolol (21 subjects 5 
mg of Bisoprolol and 12 subjects 10 mg of Bisoprolol). After a two-week 
up-titration period, subjects remained on study medication for a period of 
6 months. The primary efficacy parameter was the number of ventricular 
tachycardia episodes registrated on 24 h Holter monitoring each two 
months. There was an improved reduction in ventricular tachycardia 
episodes in the Bisoprolol group (p < 0.03). There was also an improve- 
ment in survival in all causes of death (respective crude mortality rate of 
6.2% in the Bisoprolol group compared with 14.3% in the placebo group, p 
< 0.01). Bisoprolol lowered most the risk of sudden cardiac death 69% (p < 
0.001) compared to pump failure and other causes of cardiovascular death. 
It can be concluded that in subjects with mild to moderate heart failure 
from systolic disfunction, Bisoprolol produces a reduction of venticu- 
lar tachycardia episodes, reduction of mortality and mostly reduction of 
sudden cardiac death. 
P60/10405 Dosage of ACE-inhibitors, diuretics and digitalis for 
the treatment of congestive heart failure given by 
general practitioners in teh province Styria in Austria 
M. Wonisch, EM. Fruhwald, R. Maier, N. Watzinger, W. Klein. Dep. of 
Internal Medicine, LKH Graz, Graz, Austria 
Introduction: Congestive heart failure (CHF) is one of the most common 
reasons for hospitalisation. Therefore, the medical treatment according to 
the guidelines is necessary to prevent worsening of stable CHF. 
The aim of the study was to evaluate the dosing of ACE-inhibitors, 
diuretics and digitalis for the treatment of CHF by general practitioners 
(GPs) in the province Styria in Austria. 
Methods: Surveys examining the dosage of ACE-inhibitors, diuretics, 
and digitalis were sent to all 827 GPs in the province Styria. 
Table 1: ACE-inhibitors 
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Results: Questionnaires were returned by 253 (31%) of the GPs. 
Dosages of the medications are classified to low, medium and high. Beside 
the substance-name there is the frequency of usage. The difference to 100% 
is determined by incomplete answers or by multiple nomination. 
Conclusion: Dosages of ACE-inhibitors and diuretics are mostly low 
to medium, dosage of digitalis is medium most frequently. The dosages 
of ACE-inhibitors correspond in about 2 to 11% with the recommended 
(high) doses and are in accordance with those found in international sur- 
veys. Given these results we conclude that there is space for improvement 
of treatment of CHF by Styrian GPs. 
P61/10456 Limitation of the excessive extrace&lar matrix 
turnover is a major determinant of the beneficial effect 
of spimnolactone on survival in patients with CHF: 
Insights from the RALES trial 
F. Zannad, F. Alla, B. Dousset’, B. Pitt2. Centre d’lnvestigation Clinique 
(CZC). ZNSERM-CHU Nancy; ‘Laboratoire Central de Chimie, CHU 
Nancy, France; 2 University of Michigan, Ann Arbol: United States 
Background: In congestive heart failure (CHF), extracellular matrix 
turnover is a major determinant of cardiac remodeling, diastolic function 
and pumping capacity. It may be monitored by measuring the serum level 
of procollagen type III aminoterminal peptide (PIIINP). Animal studies 
suggested that spironolactone (SPIRO), an aldosterone receptor antagonist 
may decrease cardiac and vascular fibrosis. Thus, we studied the prognostic 
significance of PIIINP and its changes during chronic treatment with 
SPIRO. 
Methods: A sample of 261 patients from the RALES trial participated 
in this substudy (CHF NYHA III and IV, mean age 69, LVEF = 26%, 
ischemic heart disease = 46%, all were on conventional therapy -92% 
on ACE inhibitors-). Patients were randomized to placebo or SPIRO 12.5 
to 50 mg daily. Serum PIIINP was measured at baseline and 6 months 
after randomization. Mean survival follow up was 24 months. ANOVA and 
multivariate Cox survival model were used. 
Results: Baseline serum PIIINP level was 5.0 &l and was similar in 
the SPIRO and placebo group. At 6 months it decreased in the SPIRO 
(-17%, p = 0.004), but not in the placebo group. Baseline level z 3.85 
&l was associated with an increased risk of death only in the placebo 
group (RR = 2.36 [1.344.18], p = 0.003). On the other hand, survival 
benefit from SPIRO was clustered to patients with above median baseline 
PIIINP levels (RR = 0.53 [0.35-0.82] vs 0.90 [0.58-1.401). These findings 
were unchanged after adjustment for other prognostic factors. 
Conclusion: In patients with CHF, elevated serum PIIINP was signif- 
icantly associated with excess mortality. SPIRO decreased serum PIIINP 
and nearly suppressed the excess death risk related to high PIIINP level. It 
is suggested that limitation of the excessive extracellular matrix turnover 
is a major determinant of the beneficial effect of SPIRO on survival in 
patients with CHF. 
P62/10460 The acute effect of lisinopril upon left ventricular 
function in patients with dilated cardiomiopathy 
D. Zdrenghea, M. Popescu, D. Timis, D. Pop, A. Papadopol. Cardiology, 
Rehabilitation Hospital, Cluj-Napoca, Romania 
Angiotensine converting enzyme inhibitors (ACEI) are frequently used 
in patients (p) with congestive heart failure (CHF), especially dilated 
cardiomiopathy (DCM). During chronic use ACE improve LV systolic 
function but the acute effect of ACE1 upon LV systolic and especially 
diastolic function, is less studied, this being the purpose of the present 
study. 
There were studied 25p with DCM, 16 in sinus rhythm and 9 with 
atria1 fibrillation. Any patient wasn’t treated with ACE1 the 7 days before 
the study. An echo Doppler examination was done and LV systolic and 
diastolic parameters were determinated. The examination was repeated 7 
hour after administration of a single oral dose of 10 mg lisinopril. 
Ejection fraction raised from 37.91 to 45.39% (p < 0.05) and shortening 
